Regulatory Alert: FDA's April 2026 Update on BPC 157 and GHK Cu Holt Law FDA to Remove 12 Popular Peptides from the Category 2 Do Not Compound List Frier Levitt FDA Peptide Update 2026: Removal from Do Not Compound List and What It Means for Pharmacies The reason peptide access is changing comes down to two regulatory categories most patients don't know exist: 503A and 503B. 503A = traditional compounding pharmacies. State licensed, patient specific prescriptions. 503B = FDA registered outsourcing BREAKING FDA UPDATE MASSIVE FOR PEPTIDES The U.S. Food & Drug Administration is reportedly reclassifying 14 peptides from Category 2 (compounding only, no legal prescribing) into Category 1. This means Peptide Therapy in Austin, TX Austin Plastic Surgeon Dr. Chuma